论文部分内容阅读
目的评价美罗培南在治疗老年性血液病患者合并中重度感染时的临床疗效及安全性。方法回顾性分析90例老年血液病患者合并感染时应用美罗培南进行治疗,剂量为1givgttQ812h静脉滴注,疗程<21d。根据国家食品药品监督管理局新药临床研究指导原则标准判定疗效。结果美罗培南治疗老年血液病合并感染的有效率为74.4%(67/90);在合并败血症7例中,6例有效。中性粒细胞绝对值<0.5×109/L以下者,有效率为72.1%(49/68)。不良反应发生率为6.7%(6/90)。结论美罗培南治疗老年血液系统疾病合并感染疗效显著而且安全性高。
Objective To evaluate the clinical efficacy and safety of Meropenem in the treatment of patients with senile hematological diseases complicated by moderate and severe infections. Methods Retrospective analysis of 90 cases of elderly patients with hematological infection with Meropenem treatment, the dose of 1givgttQ812h intravenous infusion, treatment <21d. According to the State Food and Drug Administration clinical research guidelines determine the efficacy of new drugs. Results The effective rate of Meropenem in the treatment of senile hematological infection was 74.4% (67/90). Six of 7 patients with combined sepsis were effective. Neutrophils absolute value <0.5 × 109 / L less than the effective rate was 72.1% (49/68). The incidence of adverse reactions was 6.7% (6/90). Conclusion Meropenem is effective and safe in the treatment of co-infection of the elderly with hematological diseases.